Duality of fibroblast-like synoviocytes in RA: Passive responders and imprinted aggressors

Nature Reviews Rheumatology

Volumn 9, Issue 1, 2013, Pages 24-33

  Bottini, Nunzio ^a   Firestein, Gary S ^b  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE 1; AGGRECANASE 2; CADHERIN; CADHERIN 11; COLLAGEN TYPE 4; COLLAGEN TYPE 5; COLLAGENASE 3; DECAY ACCELERATING FACTOR; DNA METHYLTRANSFERASE INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; PLATELET DERIVED GROWTH FACTOR; STROMELYSIN; THY 1 ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCOSE; URIDINE DIPHOSPHATE GLUCOSE 6 DEHYDROGENASE; VASCULAR CELL ADHESION MOLECULE 1; VIMENTIN;

ANTISENSE THERAPY; APOPTOSIS; BONE DESTRUCTION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; EPIGENETICS; FIBROBLAST LIKE SYNOVIOCYTE; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; INFLAMMATION; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SOMATIC MUTATION; SYNOVIOCYTE; TISSUE INJURY;

ARTHRITIS, RHEUMATOID; CELL MOVEMENT; FIBROBLASTS; HUMANS; HYPERPLASIA; IMMUNOLOGIC FACTORS; PHENOTYPE; SYNOVIAL MEMBRANE;

EID: 84871778727     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.190     Document Type: Review

References (85)

1. Firestein, G. S. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum. 39, 1781-1790 (1996).
2. Müller-Ladner, U. et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am. J. Pathol. 149, 1607-1615 (1996). (Pubitemid 26363967)
3. Lefèvre, S. et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat. Med. 15, 1414-1420 (2009).
4. Bartok, B. & Firestein, G. S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 233, 233-255 (2010).
5. Edwards, J. C., Leigh, R. D. & Cambridge, G. Expression of molecules involved in B lymphocyte survival and differentiation by synovial fibroblasts. Clin. Exp. Immunol. 108, 407-414 (1997). (Pubitemid 27242427)
6. Okazaki, M. et al. Molecular cloning and characterization of OB-cadherin, a new member of cadherin family expressed in osteoblasts. J. Biol. Chem. 269, 12092-12098 (1994). (Pubitemid 24196706)
7. Lee, D. M. et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 315, 1006-1010 (2007). (Pubitemid 46281192)
8. Valencia, X. et al. Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J. Exp. Med. 200, 1673-1679 (2004). (Pubitemid 40094191)
9. Chang, S. K. et al. Cadherin-11 regulates fibroblast inflammation. Proc. Natl Acad. Sci. USA 108, 8402-8407 (2011).
10. Firestein, G. S., Yeo, M. & Zvaifler, N. J. Apoptosis in rheumatoid arthritis synovium. J. Clin. Invest. 96, 1631-1638 (1995).
11. Imamura, F. et al. Monoclonal expansion of synoviocytes in rheumatoid arthritis. Arthritis Rheum. 41, 1979-1986 (1998). (Pubitemid 28506688)
12. Matsumoto, S., Müller-Ladner, U., Gay, R. E., Nishioka, K. & Gay, S. Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid synovial fibroblasts. J. Rheumatol. 23, 1345-1352 (1996). (Pubitemid 26258756)
13. Meinecke, I. et al. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proc. Natl Acad. Sci. USA 104, 5073-5078 (2007). (Pubitemid 47186178)
14. Kumkumian, G. K. et al. Platelet-derived growth factor and IL-1 interactions in rheumatoid arthritis. Regulation of synoviocyte proliferation, prostaglandin production, and collagenase transcription. J. Immunol. 143, 833-837 (1989). (Pubitemid 19203806)
15. Lotz, M. & Guerne, P. A. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA). J. Biol. Chem. 266, 2017-2020 (1991). (Pubitemid 21909022)
16. Shigeyama, Y. et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum. 43, 2523-2530 (2000).
17. Pap, T., Aupperle, K. R., Gay, S., Firestein, G. S. & Gay, R. E. Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion. Arthritis Rheum. 44, 676-681 (2001). (Pubitemid 32234627)
18. Guerne, P. A., Zuraw, B. L., Vaughan, J. H., Carson, D. A. & Lotz, M. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J. Clin. Invest. 83, 585-592 (1989). (Pubitemid 19061181)
19. Crow, M. K. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res. Ther. 12 (Suppl. 1), S5 (2010).
20. Palmer, C. D., Mutch, B. E., Page, T. H., Horwood, N. J. & Foxwell, B. M. Bmx regulates LPS-induced IL-6 and VEGF production via mRNA stability in rheumatoid synovial fibroblasts. Biochem. Biophys. Res. Commun. 370, 599-602 (2008).
21. Nikitopoulou, I. et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J. Exp. Med. 209, 925-933 (2012).
22. Stanczyk, J., Ospelt, C., Gay, R. E. & Gay, S. Synovial cell activation. Curr. Opin. Rheumatol. 18, 262-267 (2006). (Pubitemid 43740378)
23. Johnson, G. L. & Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912 (2002). (Pubitemid 35425238)
24. Han, Z. et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest 108, 73-81 (2001). (Pubitemid 32634924)
25. Yoshizawa, T. et al. Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression. J. Immunol. 183, 1360-1367 (2009).
26. Korb, A. et al. Differential tissue expression and activation of p38 MAPK a, ß, y, and & isoforms in rheumatoid arthritis. Arthritis Rheum. 54, 2745-2756 (2006). (Pubitemid 44497753)
27. Westra, J., Limburg, P. C., de Boer, P. & van Rijswijk, M. H. Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann. Rheum. Dis. 63, 1453-1459 (2004). (Pubitemid 39433951)
28. Inoue, T., Hammaker, D., Boyle, D. L. & Firestein, G. S. Regulation of p38 MAPK by MAPK kinases 3 and 6 in fibroblast-like synoviocytes. J. Immunol. 174, 4301-4306 (2005). (Pubitemid 40396012)
29. Guma, M. et al. Pro-and anti-inflammatory functions of the p38 pathway in rheumatoid arthritis: advantages of targeting upstream kinases MKK3 or MKK6. Arthritis Rheum. 64, 2887-2895 (2012).
30. Cohen, S. B. et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 60, 335-344 (2009).
31. Genovese, M. C. et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J. Rheumatol. 38, 846-854 (2011).
32. Shahrara, S., Castro-Rueda, H. P., Haines, G. K. & Koch, A. E. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Arthritis Res. Ther. 9, R112 (2007).
33. Pap, T. et al. Cooperation of Ras-and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum. 50, 2794-2802 (2004). (Pubitemid 39209516)
34. Weisbart, R. H. et al. BRAF drives synovial fibroblast transformation in rheumatoid arthritis. J. Biol. Chem. 285, 34299-34303 (2010).
35. Abreu, J. R. et al. The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue. Arthritis Res. Ther. 11, R121 (2009).
36. Han, Z. et al. Jun N-terminal kinase in rheumatoid arthritis. J. Pharmacol. Exp. Ther. 291, 124-130 (1999). (Pubitemid 29451581)
37. Svensson, C. I. et al. Gadd45ß deficiency in rheumatoid arthritis: enhanced synovitis through JNK signaling. Arthritis Rheum. 60, 3229-3240 (2009).
38. Luo, Y. et al. Suppression of collagen-induced arthritis in growth arrest and DNA damage-inducible protein 45ß-deficient mice. Arthritis Rheum. 63, 2949-2955 (2011).
39. Aupperle, K. et al. NF-KB regulation by I?B kinase-2 in rheumatoid arthritis synoviocytes. J. Immunol. 166, 2705-2711 (2001). (Pubitemid 32173511)
40. Oeckinghaus, A. & Ghosh, S. The NF-κB family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol. 1, a000034 (2009).
41. Okazaki, Y. et al. Effect of nuclear factor-?B inhibition on rheumatoid fibroblast-like synoviocytes and collagen induced arthritis. J. Rheumatol. 32, 1440-1447 (2005). (Pubitemid 41113962)
42. Zhang, H. G. et al. Gene therapy that inhibits nuclear translocation of nuclear factor KB results in tumor necrosis factor a-induced apoptosis of human synovial fibroblasts. Arthritis Rheum. 43, 1094-1105 (2000).
43. Pap, T. et al. Activation of synovial fibroblasts in rheumatoid arthritis: lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res. 2, 59-64 (2000). (Pubitemid 32223701)
44. Bartok, B. et al. PI3 kinase 5 is a key regulator of synoviocyte function in rheumatoid arthritis. Am. J. Pathol. 180, 1906-1916 (2012).
45. Sweeney, S. E., Hammaker, D., Boyle, D. L. & Firestein, G. S. Regulation of c-Jun phosphorylation by the I?B kinase-e complex in fibroblast-like synoviocytes. J. Immunol. 174, 6424-6430 (2005). (Pubitemid 40663836)
46. Sweeney, S. E., Corr, M. & Kimbler, T. B. Role of interferon regulatory factor 7 in serum-transfer arthritis: regulation of interferon-ß production. Arthritis Rheum. 64, 1046-1056 (2012).
47. Korb, A., Pavenstadt, H. & Pap, T. Cell death in rheumatoid arthritis. Apoptosis 14, 447-454 (2009).
48. Wakisaka, S. et al. Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA). Clin. Exp. Immunol. 114, 119-128 (1998). (Pubitemid 28442823)
49. Audo, R. et al. Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. Arthritis Rheum. 63, 904-913 (2011).
50. Han, Z., Boyle, D. L., Shi, Y, Green, D. R. & Firestein, G. S. Dominant-negative p53 mutations in rheumatoid arthritis. Arthritis Rheum. 42, 1088-1092 (1999). (Pubitemid 29268944)
51. Firestein, G. S. et al. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am. J. Pathol. 149, 2143-2151 (1996). (Pubitemid 26415230)
52. Cha, H. S., Rosengren, S., Boyle, D. L. & Firestein, G. S. PUMA regulation and proapoptotic effects in fibroblast-like synoviocytes. Arthritis Rheum. 54, 587-592 (2006). (Pubitemid 43228635)
53. Schedel, J. et al. FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis. Arthritis Rheum. 46, 1512-1518 (2002). (Pubitemid 34620197)
54. Franz, J. K. et al. Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. Arthritis Rheum. 43, 599-607 (2000). (Pubitemid 30394952)
55. Maciejewska-Rodrigues, H. et al. Epigenetics and rheumatoid arthritis: the role of SENP1 in the regulation of MMP-1 expression. J. Autoimmun. 35, 15-22 (2010).
56. Fassbender, H. G. & Simmling-Annefeld, M. The potential aggressiveness of synovial tissue in rheumatoid arthritis. J. Pathol. 139, 399-406 (1983). (Pubitemid 13160684)
57. Yamanishi, Y. et al. p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis. Arthritis Res. Ther. 7, R12-R18 (2005).
58. Da Sylva, T. R., Connor, A., Mburu, Y., Keystone, E. & Wu, G. E. Somatic mutations in the mitochondria of rheumatoid arthritis synoviocytes. Arthritis Res. Ther. 7, R844-R851 (2005).
59. Lee, S. H. et al. Microsatellite instability and suppressed DNA repair enzyme expression in rheumatoid arthritis. J. Immunol. 170, 2214-2220 (2003).
60. Tak, P. P., Zvaifler, N. J., Green, D. R. & Firestein, G. S. Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol. Today 21, 78-82 (2000). (Pubitemid 30069620)
61. Harty, L. C. et al. Mitochondrial mutagenesis correlates with the local inflammatory environment in arthritis. Ann. Rheum. Dis. 71, 582-588 (2012).
62. Karouzakis, E., Gay, R. E., Gay, S. & Neidhart, M. Epigenetic deregulation in rheumatoid arthritis. Adv. Exp. Med. Biol. 711, 137-149 (2011).
63. Kuchen, S. et al. The L1 retroelement-related p40 protein induces p38δ MAP kinase. Autoimmunity 37, 57-65 (2004). (Pubitemid 38185911)
64. Nakano, K., Whitaker, J. W., Boyle, D. L., Wang, W. & Firestein, G. S. DNA methylome signature in rheumatoid arthritis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2012-201526.
65. Grabiec, A. M., Korchynskyi, O., Tak, P. P. & Reedquist, K. A. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann. Rheum. Dis. 71, 424-431 (2012).
66. Nakamachi, Y. et al. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 60, 1294-1304 (2009).
67. Stanczyk, J. et al. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum. 63, 373-381 (2011).
68. Duroux-Richard, I., Jorgensen, C. & Apparailly, F. What do microRNAs mean for rheumatoid arthritis? Arthritis Rheum. 64, 11-20 (2012).
69. Karouzakis, E., Gay, R. E., Gay, S. & Neidhart, M. Increased recycling of polyamines is associated with global DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 64, 1809-1817 (2012).
70. Ballestar, E. An introduction to epigenetics. Adv. Exp. Med. Biol. 711, 1-11 (2011).
71. Bogdanos, D. P. et al. Twin studies in autoimmune disease: genetics, gender and environment. J. Autoimmun. 38, 156-169 (2012).
72. Guma, M., Ronacher, L. M., Firestein, G. S., Karin, M. & Corr, M. JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis. Arthritis Rheum. 63, 1603-1612 (2011).
73. Denninger, K. et al. JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis. Am. J. Pathol. 179, 1884-1893 (2011).
74. Lee, S. I., Boyle, D. L, Berdeja, A. & Firestein, G. S. Regulation of inflammatory arthritis by the upstream kinase mitogen activated protein kinase kinase 7 in the c-Jun N-terminal kinase pathway. Arthritis Res. Ther. 14, R38 (2012).
75. Haruta, K. et al. Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats. Inflamm. Res. 61, 551-562 (2012).
76. Cha, H. S. et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J. Pharmacol. Exp. Ther. 317, 571-578 (2006).
77. Weinblatt, M. E. et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363, 1303-1312 (2010).
78. Schieven, G. L. The p38a kinase plays a central role in inflammation. Curr. Top. Med. Chem. 9, 1038-1048 (2009).
79. Damjanov, N., Kauffman, R. S. & Spencer-Green, G. T. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 60, 1232-1241 (2009).
80. Inoue, T. et al. Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. Proc. Natl Acad. Sci. USA 103, 5484-5489 (2006).
81. Hah, Y. S. et al. A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum. 62, 2313-2321 (2010).
82. Tak, P. P. et al. Inhibitor of nuclear factor KB kinase ß is a key regulator of synovial inflammation. Arthritis Rheum. 44, 1897-1907 (2001). (Pubitemid 32758238)
83. Shi, J. et al. Epirubicin potentiates recombinant adeno-associated virus type 2/5-mediated TRAIL expression in fibroblast-like synoviocytes and augments the antiarthritic effects of rAAV2/5-TRAIL. Arthritis Rheum. 64, 1345-1354 (2012).
84. Lin, H. S. et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150, 862-872 (2007).
85. Kavanaugh, A. F. et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 37, 992-999 (1994). (Pubitemid 24222089)